Novel Therapies Targeting the Alternate Renin Angiotensin System in Chronic Liver Disease

Grant number: 1124125 | Funding period: 2017 - 2022

Completed

Abstract

Scarring of the liver due to chronic liver diseases (cirrhosis) is now a major cause of illness and death in Australia. This project will study whether drugs and gene therapy approaches targeting a hormone system called the renin angiotensin system can be used to prevent the development of cirrhosis and its complications.

Related publications (9)

Scholarly works icon

Oncogenic plasmid DNA and liver injury agent dictates liver cancer development in a mouse model

V Chiu, C Yee, N Main, I Stevanovski, M Watt, T Wilson, P Angus, T Roberts, N Shackel, C Herath

2024-10-01

Primary liver cancer is an increasing problem worldwide and is associated with significant mortality. A popular method of modeling..

Scholarly works icon

Editorial: Pathophysiology and pharmacological treatments associated with liver failures

CB Herath, O El Hiba, X Zhou, X Luo, K Lu

2024-01-01

Scholarly works icon

Mas-related G protein-coupled receptor type D antagonism improves portal hypertension in cirrhotic rats

LS Gunarathne, IG Rajapaksha, S Casey, T Qaradakhi, A Zulli, H Rajapaksha, J Trebicka, PW Angus, CB Herath

2022-09-01

Splanchnic vasodilatation contributes to the development and aggravation of portal hypertension (PHT). We previously demonstrated ..

Scholarly works icon

Angiotensin Converting Enzyme-2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver

IG Rajapaksha, LS Gunarathne, K Asadi, R Laybutt, S Andrikopoulous, IE Alexander, MJ Watt, PW Angus, CB Herath

2022-05-01

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and is frequently associated with type ..

Scholarly works icon

Editorial: Portal Hypertension in Cirrhosis: From Pathogenesis to Novel Treatments

CB Herath, PW Angus, J Trebicka

2022-03-21

Scholarly works icon

Update on new aspects of the renin-angiotensin system in hepatic fibrosis and portal hypertension: Implications for novel therapeutic options

IG Rajapaksha, LS Gunarathne, PW Angus, CB Herath

2021-02-02

There is considerable experimental evidence that the renin angiotensin system (RAS) plays a central role in both hepatic fibrogene..

Scholarly works icon

Liver-Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug-Resistant Gene 2-Knockout Mice

IG Rajapaksha, LS Gunarathne, K Asadi, SC Cunningham, A Sharland, IE Alexander, PW Angus, CB Herath

2019-12-01

There is a large unmet need for effective therapies for cholestatic disorders, including primary sclerosing cholangitis (PSC), a d..

Scholarly works icon

Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats

LS Gunarathne, PW Angus, CB Herath

2019-09-20

Portal hypertension (PHT) resulting from splanchnic vasodilatation is a major cause of morbidity and mortality in patients with ci..

Scholarly works icon

The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice

IG Rajapaksha, KY Mak, P Huang, LM Burrell, PW Angus, CB Herath

2018-12-01

There is no established medical therapy to treat biliary fibrosis resulting from chronic inflammation in the biliary tree. We have..

University of Melbourne Researchers